Table 1.
Baseline characteristics in a subset of Look AHEAD participants with adiponectin data
| Overall sample with adiponectin data (n = 1,397) | ||||||
|---|---|---|---|---|---|---|
| Men and women |
Men |
Women |
||||
| ILI (n = 732) | DSE (n = 665) | ILI (n = 315) | DSE (n = 284) | ILI (n = 417) | DSE (n = 381) | |
| Age (years) | 57.1 (7.1) | 57.3 (7.3) | 58.7 (7.0) | 58.7 (7.2) | 56.0 (7.0) | 56.3 (7.2) |
| Female sex (%) | 57 | 57 | ||||
| Race/ethnicity | ||||||
| Caucasian (%) | 68 | 66 | 77 | 76 | 62 | 58 |
| African American (%) | 11 | 12 | 7 | 7 | 15 | 16 |
| Hispanic (%) | 10 | 10 | 10 | 8 | 12 | 10 |
| History of CVD† (%) | 12 | 11 | 19 | 17 | 7 | 6 |
| Current tobacco use* (%) | 4 | 3 | 3 | 4 | 4 | 2 |
| Statin therapy (%) | 41 | 40 | 45 | 48 | 38 | 35 |
| Thiazolidinedione therapy (%) | 24 | 27 | 27 | 27 | 23 | 26 |
| Insulin therapy (%) | 15 | 14 | 15 | 14 | 16 | 15 |
| Estrogen replacement (%) | — | — | — | — | 53 | 59 |
| Diabetes duration* (years) | 6.6 (6.3) | 6.6 (6.3) | 6.8 (6.3) | 6.5 (6.9) | 6.4 (6.4) | 6.6 (6.6) |
| HDL-cholesterol (mg/dL) | 42.6 (11.4) | 42.1 (11.3) | 37.2 (8.8) | 36.9 (8.7) | 46.6 (11.5) | 46.0 (11.5) |
| Triglycerides (mg/dL, median [IQR]) | 160 (111, 232) | 154 (106, 219) | 168 (114, 236) | 159 (108, 235) | 154 (109, 221) | 145 (105, 205) |
| LDL-cholesterol (mg/dL) | 112 (30.3) | 112.7 (33.0) | 107.9 (28.2) | 107.8 (33.5) | 115.0 (31.1) | 116.3 (32.2) |
| HbA1c (%) | 7.3 (1.2) | 7.3 (1.2) | 7.3 (1.2) | 7.4 (1.2) | 7.3 (1.1) | 7.3 (1.2) |
| HbA1c (mmol/mol) | 56 (13.1) | 56 (13.1) | 56 (13.1) | 57 (13.1) | 56 (12.0) | 56 (13.1) |
| Weight (kg) | 102.9 (20.4) | 101.3 (18.6) | 111.0 (20.0) | 107.6 (18.0) | 96.7 (18.4) | 96.7 (17.7) |
| BMI (kg/m2) | 36.4 (6.4) | 36.0 (5.9) | 35.8 (6.0) | 34.8 (5.1) | 36.9 (6.6) | 37.0 (6.3) |
| Waist circumference (cm) | 115.1 (14.8) | 114.5 (14.1) | 119.7 (14.4) | 118.2 (14.0) | 111.6 (14.2) | 111.8 (13.5) |
| Fitness (submaximal, MET) | 5.2 (1.5) | 5.2 (1.5) | 5.7 (1.6) | 5.8 (1.7) | 4.9 (1.3) | 4.7 (1.3) |
| Adiponectin (µg/mL, median [IQR]) | 4.6 (3.3, 6.6) | 4.8 (3.5, 7.0) | 4.04 (3.00, 5.77) | 4.30 (2.91, 5.87) | 5.08 (3.73, 7.30) | 5.21 (3.86, 7.76) |
| HMW-adiponectin (µg/mL, median [IQR]) | 1.9 (1.1, 3.1) | 1.9 (1.2, 3.2) | 1.50 (0.93, 2.62) | 1.60 (0.97, 2.69) | 2.14 (1.34, 3.35) | 2.21 (1.44, 3.48) |
| Subset with adiponectin and body composition data (n = 494) | ||||||
| Men and women |
Men |
Women |
||||
| ILI (n = 247) | DSE (n = 247) | ILI (n = 80) | DSE (n = 91) | ILI (n = 167) | DSE (n = 156) | |
| Body composition | ||||||
| Total body fat (kg) | 39.80 (10.92) | 40.19 (10.99) | 35.92 (9.00) | 35.64 (8.79) | 41.66 (11.29) | 42.84 (11.29) |
| Total lean body mass (kg) | 53.08 (10.39) | 54.08 (10.09) | 64.39 (5.97) | 63.95 (7.54) | 47.66 (7.20) | 48.32 (6.18) |
Continuous data are shown as mean (SD), unless otherwise noted.
To convert mg/dL to mmol/L, multiply by 0.02587 for cholesterol and 0.01129 for triglycerides.
IQR, interquartile range.
*By self-report.
†Self-reported history of myocardial infarction, stroke, transient ischemic attack, angioplasty/stent, coronary artery bypass graft, carotid endarterectomy, abdominal aortic aneurysm, or heart failure.